NCT02722941 is a Phase 2 clinical trial of Panobinostat in Multiple Myeloma, sponsored by H. Lee Moffitt Cancer Center and Research Institute.

Who is sponsoring NCT02722941?

NCT02722941 is sponsored by H. Lee Moffitt Cancer Center and Research Institute.

What drugs are being tested in NCT02722941?

Interventions in NCT02722941: Panobinostat.

What condition does NCT02722941 study?

NCT02722941 studies Multiple Myeloma.

Is NCT02722941 still recruiting?

NCT02722941 is currently completed. Last updated 1 November 2022.

Are results published for NCT02722941?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2022-11-01 · How we verify

NCT02722941

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT)

Completed Phase 2 Results posted Last updated 1 November 2022

What this trial tests

Phase 2 trial testing Panobinostat in Multiple Myeloma in 30 participants. Completed in 18 January 2021.

Timeline

10 June 2016

Primary endpoint
7 June 2020

18 January 2021

Quick facts

Lead sponsor	H. Lee Moffitt Cancer Center and Research Institute
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	10 June 2016
Primary completion	7 June 2020
Estimated completion	18 January 2021
Sites	1 location across United States

Drugs / interventions tested

Panobinostat (PANOBINOSTAT) — full drug profile →

Conditions studied

Multiple Myeloma — all drugs for Multiple Myeloma →

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Who can join

18 and older, any sex, with Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Relative Dose Intensity (RDI) Per Cohort Primary · Up to 2 years

Investigators will calculate RDI for each cohort. Relative dose intensity (RDI) represents the ratio of the amount of a drug actually delivered \[actual dose intensity (DI)\] to the amount planned (planned DI). The purpose of calculating RDI is to evaluate whether the planned DI of a chemotherapy treatment was actually achieved which may suggest the feasibility of planned treatment regimen. There are multitude of reports demonstrating a correlation between RDI and survival in cancer treatment. RDI = (total dose received by the patient = mg)/(planned full dose of drug = mg).

Group	Value	95% CI
Cohort A: Maintenance Therapy	97.9	77.1 – 100
Cohort B: Maintenance Therapy	89.6	63.1 – 100

Complete Response Rate Secondary · Up to 5 years

Complete Response (CR) rate to panobinostat maintenance therapy after autologous HCT. CR: Negative immunofixation of serum and urine, disappearance of any soft tissue plasmacytomas, and \< 5% plasma cells in bone marrow.

Group	Value	95% CI
Cohort A: Maintenance Therapy	73.33	44.9 – 92.2
Cohort B: Maintenance Therapy	66.6	38.4 – 88.2

Progression Free Survival (PFS) Secondary · at 2 years

Progressive Disease (PD) according to Uniform Response Reporting Criteria for Multiple Myeloma by the International Myeloma Working Group (IMWG). Increase of 25% from lowest response value in any of the following: * Serum M- component (absolute increase must be ≥ 0.5 g/dL) * Urine M-component (absolute increase must be ≥ 200 mg/24 h) * Only in patients without measurable serum and urine M protein levels and without measurable disease by free light chain (FLC) levels, bone marrow plasma cell percentage (absolute percentage must be ≥ 10% ) * Definite development of new bone lesions or soft tiss

Group	Value	95% CI
Cohort A: Maintenance Therapy	71.8	41.1 – 88.4
Cohort B: Maintenance Therapy	53.3	26.3 – 74.4

Overall Survival (OS) Secondary · at 2 years

OS: The length of time from either the date of diagnosis or the start of treatment for a disease, such as cancer, that patients diagnosed with the disease are still alive.

Group	Value	95% CI
Cohort A: Maintenance Therapy	100	NA – NA
Cohort B: Maintenance Therapy	100	NA – NA

Adverse events — posted to ClinicalTrials.gov

Time frame: Adverse events collected from date of consent until off study date, 4 years, 2 months.. Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Cohort A: Maintenance Therapy

Serious: 2/15 (13%)

Deaths: 0/15

Cohort B: Maintenance Therapy

Serious: 3/15 (20%)

Deaths: 0/15

Serious adverse events (7 terms)

Reaction	System	Cohort A: Maintenance Ther…	Cohort B: Maintenance Ther…
Lung infection	Infections and infestations	—	—
Flu like symptoms	General disorders	—	—
Colitis	Gastrointestinal disorders	—	—
Headache	Nervous system disorders	—	—
Fever	General disorders	—	—
Bone pain	Musculoskeletal and connective tissue disorders	—	—
Cholecystitis	Gastrointestinal disorders	—	—

Other adverse events (46 terms — click to expand)

Reaction	System	Cohort A: Maintenance Ther…	Cohort B: Maintenance Ther…
White blood cell decreased	Investigations	—	—
Cholesterol high	Investigations	—	—
Hypertension	Vascular disorders	—	—
Hyperglycemia	Metabolism and nutrition disorders	—	—
Anemia	Blood and lymphatic system disorders	—	—
Fatigue	General disorders	—	—
Platelet count decreased	Investigations	—	—
Back Pain	Musculoskeletal and connective tissue disorders	—	—
Peripheral motor neuropathy	Nervous system disorders	—	—
Lymphocyte count decreased	Investigations	—	—
Upper respiratory infection	Infections and infestations	—	—
Neutrophil count decreased	Investigations	—	—
Hypophosphatemia	Metabolism and nutrition disorders	—	—
Bone pain	Musculoskeletal and connective tissue disorders	—	—
Diarrhea	Gastrointestinal disorders	—	—
Gastroesophageal reflux disease	Gastrointestinal disorders	—	—
Arthritis	Musculoskeletal and connective tissue disorders	—	—
Insomnia	Psychiatric disorders	—	—
Hypertriglyceridemia	Metabolism and nutrition disorders	—	—
Headache	Nervous system disorders	—	—
Thrombocytopenia	Investigations	—	—
Neck pain	Musculoskeletal and connective tissue disorders	—	—
Peripheral sensory neuropathy	Nervous system disorders	—	—
Hypercalcemia	Metabolism and nutrition disorders	—	—
Creatinine increased	Investigations	—	—
Chronic kidney disease	Renal and urinary disorders	—	—
Hypokalemia	Metabolism and nutrition disorders	—	—
Hypocalcemia	Metabolism and nutrition disorders	—	—
Hyperkalemia	Metabolism and nutrition disorders	—	—
Nausea	Gastrointestinal disorders	—	—
Productive cough	Respiratory, thoracic and mediastinal disorders	—	—
Fracture	Musculoskeletal and connective tissue disorders	—	—
Polyuria and nocturia	Renal and urinary disorders	—	—
INR increased	Investigations	—	—
Musculoskeletal and connective tissue disorders -Other	Musculoskeletal and connective tissue disorders	—	—
Cholecystitis	Hepatobiliary disorders	—	—
Cholecystectomy	Gastrointestinal disorders	—	—
Atrial fibrilation	Cardiac disorders	—	—
Arthalgia	Musculoskeletal and connective tissue disorders	—	—
Fibromyalgia	Nervous system disorders	—	—

Most-reported serious reactions: Lung infection, Flu like symptoms, Colitis, Headache, Fever, Bone pain, Cholecystitis.

Data from ClinicalTrials.gov NCT02722941 adverse events section.

Sponsor's own description

The purpose of this study is to learn more about ways to prevent or delay relapse of multiple myeloma (MM). This study will determine the best dosing schedule of LBH589 maintenance therapy as well as the safety (side effects) and tolerability of LBH589 maintenance therapy after autologous hematopoietic cell transplant (HCT).

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies.
Zhao A, Zhou H, Yang J, Li M, et al · · 2023 · cited 81× · PMID 36797244 · DOI 10.1038/s41392-023-01342-6
New Insights Into the Role of Phenotypic Plasticity and EMT in Driving Cancer Progression.
Bhatia S, Wang P, Toh A, Thompson EW. · · 2020 · cited 63× · PMID 32391381 · DOI 10.3389/fmolb.2020.00071
Efficacy of Panobinostat for the Treatment of Multiple Myeloma.
Eleutherakis-Papaiakovou E, Kanellias N, Kastritis E, Gavriatopoulou M, et al · · 2020 · cited 56× · PMID 32411240 · DOI 10.1155/2020/7131802
Posttransplant maintenance therapy in multiple myeloma: the changing landscape.
Sengsayadeth S, Malard F, Savani BN, Garderet L, et al · · 2017 · cited 25× · PMID 28338672 · DOI 10.1038/bcj.2017.23
Investigating the Interplay between Myeloma Cells and Bone Marrow Stromal Cells in the Development of Drug Resistance: Dissecting the Role of Epigenetic Modifications.
Schütt J, Nägler T, Schenk T, Brioli A. · · 2021 · cited 8× · PMID 34439223 · DOI 10.3390/cancers13164069

Verify or expand the search:

Other trials of Panobinostat

Trials testing the same drug.

NCT05725200 — Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer · Phase 2 · recruiting
NCT04341311 — Phase I Study of Marizomib + Panobinostat for Children With DIPG · Phase 1 · terminated
NCT03878524 — Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial · Phase 1 · terminated
NCT04897880 — A Study of Panobinostat in Pediatric Patients With Solid Tumors Including MRT/ATRT · Phase 2 · terminated
NCT04326764 — Panobinostat Maintenance After HSCT fo High-risk AML and MDS · Phase 3 · terminated

Other recruiting trials for Multiple Myeloma

Currently open trials in the same condition.

NCT07200102 — Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma · Phase 1 · recruiting
NCT07340853 — CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
NCT07454382 — A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma · Phase 2 · recruiting
NCT07266441 — A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
NCT07258511 — A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With · Phase 3 · recruiting

Other H. Lee Moffitt Cancer Center and Research Institute trials

Trials by the same sponsor.

NCT05041335 — Wet Heparinized Suction for Abdominal Cancer · NA · not yet recruiting
NCT07222995 — Hybrid Effectiveness-Implementation Trial to Integrate Precision Skin Cancer Risk Feedback in FQHCs · NA · recruiting
NCT06047977 — Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors · Phase 1 · recruiting
NCT06121180 — Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma · Phase 2 · recruiting
NCT06193486 — Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02722941 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by H. Lee Moffitt Cancer Center and Research Institute
Last refreshed: 1 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02722941.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing